BSP Pharmaceuticals is a CDMO, technologically developed to meet needs of groundbreakers and specialized in manufacturing Oncology and Immunotherapy drug, including autoimmune disease, immunotherapy & CNS among others, with a specific focus on innovative compounds.
With full containment facility, applying the most advanced and safe technologies, BSP can offer capabilities with a wide range of batch sizes providing flexibility to sustain preclinical, clinical and commercial manufacturing.
The facility is designed to handle small molecules and large molecules, including ADCs (from Conjugation to Fill Finish), mAbs (including bi-specific), synthetic peptides, oligonucleotides, lipidic nanomedicine
Production area includes:
- a plant dedicated to Cytotoxic compounds, small and large molecules, (OEL <10ng/m3) with seven sterile manufacturing suites for injectable formulation (liquid and lyophilized); an oral department for solid formulation (tablets, capsules, Liquid filled hard gelatin capsules); BDS suites for liposomes and conjugation of ADCs.
- a plant dedicated to non-Cytotoxic compounds, small and large molecules, (up to OEB 6) with seven sterile manufacturing suites for injectable formulation (liquid and lyophilized)
Ancyllary areas to support manufacturing services for an integrated supply.include:
- Development laboratories
- QC laboratories (chemical, micro and bioanalytical)
- Warehouse (storage @ RT, 2-8°C, -20°C, up to -85°C)
The plant is approved by several regulatory authorities (including EMA, FDA, PDMA Japan, ANVISA Brazil) and produce for more than 80 Countries Worldwide
BSP sets out to be a valuable point of reference to serve innovators involved in research on new generation therapies, applying the most advanced and safe technologies, in compliance with the highest Quality requirements.
With full containment facility, applying the most advanced and safe technologies, BSP can offer capabilities with a wide range of batch sizes providing flexibility to sustain preclinical, clinical and commercial manufacturing.
The facility is designed to handle small molecules and large molecules, including ADCs (from Conjugation to Fill Finish), mAbs (including bi-specific), synthetic peptides, oligonucleotides, lipidic nanomedicine
Production area includes:
- a plant dedicated to Cytotoxic compounds, small and large molecules, (OEL <10ng/m3) with seven sterile manufacturing suites for injectable formulation (liquid and lyophilized); an oral department for solid formulation (tablets, capsules, Liquid filled hard gelatin capsules); BDS suites for liposomes and conjugation of ADCs.
- a plant dedicated to non-Cytotoxic compounds, small and large molecules, (up to OEB 6) with seven sterile manufacturing suites for injectable formulation (liquid and lyophilized)
Ancyllary areas to support manufacturing services for an integrated supply.include:
- Development laboratories
- QC laboratories (chemical, micro and bioanalytical)
- Warehouse (storage @ RT, 2-8°C, -20°C, up to -85°C)
The plant is approved by several regulatory authorities (including EMA, FDA, PDMA Japan, ANVISA Brazil) and produce for more than 80 Countries Worldwide
BSP sets out to be a valuable point of reference to serve innovators involved in research on new generation therapies, applying the most advanced and safe technologies, in compliance with the highest Quality requirements.
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
